Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery
Status:
Terminated
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This study combines the deoxyribonucleic acid (DNA) methyltransferase inhibitor,
5-azacitidine (5-AZA), with an orally bioavailable histone deacetylase inhibitor, entinostat
(SNDX-275), for the adjuvant treatment of patients with resected stage I non-small cell lung
cancer (NCSLC).